Plasma half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-17 and is reviewed periodically as new material appears.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The dawn phenomenon, sometimes called the dawn effect, is an observed increase in blood sugar (glucose) levels that takes place in the early-morning, often between 2 a.m. and 8 a.m. First described by Schmidt in 1981 as an increase of blood glucose or insulin demand occurring at dawn, this naturally occurring phenomenon is frequently seen among the general population and is clinically relevant for patients with diabetes as it can affect their medical management. In contrast to Chronic Somogyi rebound, the dawn phenomenon is not associated with nocturnal hypoglycemia.
=== OECD Chief Economist === British economist Christopher Dow served as Chief Economist of the OECD from its establishment until 1973. In 1980, Canadian economist Sylvia Ostry became the first woman to be appointed OECD Chief Economist, holding the position until 1983. In 1992, Kumiharu Shigehara, former Chief Economist of the Bank of Japan, became the first individual from outside the English-speaking world to be appointed OECD Chief Economist. At the time of his appointment, the Financial Times, in an article entitled "Japan’s Turn" (22 January 1992), described him as exemplifying a new generation of Japanese figures characterised by self-confidence, strong international awareness, and a willingness to express their views openly. In February 2026, Italian Stefano Scarpetta was announced as the next Chief Economist. Scarpetta used to lead the Directorate's work on employment, migration and health.
== Pathogenic resistance == While the exact mechanisms have yet to be determined, peroxidases are known to play a part in increasing a plant's defenses against pathogens. Many members of the Solanaceae, notably Solanum melongena (eggplant/aubergine) and Capsicum chinense (the habanero/Scotch bonnet varieties of chili peppers) use Guaiacol and the enzyme guaiacol peroxidase as a defense against bacterial parasites such as Ralstonia solanacearum: the gene expression for this enzyme commences within minutes of bacterial attack.
==== Employee training ==== All employees whose jobs in health care facilities expose them to hazardous drugs must receive training. Training should include shipping and receiving personnel, housekeepers, pharmacists, assistants, and all individuals involved in the transportation and storage of antineoplastic drugs. These individuals should receive information and training to inform them of the hazards of the drugs present in their areas of work. They should be informed and trained on operations and procedures in their work areas where they can encounter hazards, different methods used to detect the presence of hazardous drugs and how the hazards are released, and the physical and health hazards of the drugs, including their reproductive and carcinogenic hazard potential. Additionally, they should be informed and trained on the measures they should take to avoid and protect themselves from these hazards. This information ought to be provided when health care workers come into contact with the drugs, that is, perform the initial assignment in a work area with hazardous drugs. Moreover, training should also be provided when new hazards emerge as well as when new drugs, procedures, or equipment are introduced.
=== Composition === The Composition C-4 used by the United States Armed Forces contains 91% RDX ("Research Department Explosive", an explosive nitroamine), bound by a mixture of 5.3% dioctyl sebacate (DOS) or dioctyl adipate (DOA) as the plasticizer (to increase the plasticity of the explosive), thickened with 2.1% polyisobutylene (PIB, a synthetic rubber) as the binder, and 1.6% of a mineral oil often called "process oil". Instead of "process oil", low-viscosity motor oil is used in the manufacture of C-4 for civilian use. The British PE4 consists of 88.0% RDX, 1.0% pentaerythrite dioleate and 11.0% DG-29 lithium grease (corresp. to 2.2% lithium stearate and 8.8% mineral oil BP) as the binder; a taggant (2,3-dimethyl-2,3-dinitrobutane, DMDNB) is added at a minimum of 0.10% weight of the plastic explosive, typically at 1.0% mass. The newer PE7 consists of 88.0% RDX, 1.0% DMDNB taggant and 11.0% of a binder composed of low molecular mass hydroxyl-terminated polybutadiene, along with an antioxidant and an agent preventing hardening of the binder upon prolonged storage. The PE8 consists of 86.5% RDX, 1.0% DMDNB taggant and 12.5% of a binder composed of di(2-ethylhexyl) sebacate thickened with high molecular mass polyisobutylene. Technical data according to the Department of the Army for the Composition C-4 follows.
Sources: en.wikipedia.org
=== Global food distribution === Along with Archer Daniels Midland, Bunge, and Cargill, the Louis Dreyfus Company is one of the four "ABCD" companies that dominate world agricultural commodity trading.
=== Derivatives === Various alginate-based materials can be produced, including porous scaffold material, alginate hydrogel, nonwoven fabric, and alginate membranes. Techniques used to produce these include ion cross-linking, microfluidic spinning, freeze drying, wet spinning, and immersive centrifugal jet spinning. Calcium salts added to a sodium alginate solution to induce ionic cross-linking, which produces the hydrogel. Freeze-drying the hydrogel to eliminate water produces the porous scaffold material. Wet spinning consists of extruding an alginate solution from a spinneret into a calcium salt solution to induce ionic cross-linking (forming the gel), and then drawing the fibers out of the bath with draft rollers. Microfluidic spinning, a simpler and more eco-friendly implementation of the process, involves introducing calcium salt flows flowing alongside and touching a central "core" flow of alginate. These flows form a "sheath". The fiber then emerges from the core flow. This technique can be used to produce shaped and grooved fibers.
== Finnigan Instrument Corporation == In 1967, Finnigan formed Finnigan Instrument Corporation with venture capital from Roger Sant and T. Z. Chu. He was joined by Michael Story from EAI, and William Fies from SRI. In early 1968, Finnigan Instrument Corporation delivered its first prototype quadrupole GC/MS instruments. One was sent to Nobel Prize winner Joshua Lederberg at Stanford University. The other was sent to Purdue University. The first commercial model for a computerized GC/MS, Finnigan's Model 1015/System 150, was introduced soon after for a price of $100,000. The first delivery went to Evan Charles Horning and Marjorie G. Horning at Baylor Medical College. For three years, Finnigan was the only company producing a computerized GC/MS. The next one to be introduced came from the Hewlett-Packard Company in 1971. Quadrupole mass spectrometry offered advantages in terms of size, cost, speed and sensitivity compared to the magnetic-sector mass spectrometry equipment most commonly used at that time. Quadrupoles offered high sensitivity and high-pressure tolerance. They could operate with a low voltage ion source. Rapid scanning became feasible because computers could be used to step the spectrometer from one ion peak to the next. This allowed acquisition and display of data in real-time, and gave operators the potential to interact with the system and modify what was being monitored. A major strength of the instrument was precise quantitation.
Neither the extent of coronary disease nor the appearance of the collateral vessels during angiography differed between the two groups, leading Kolibash to conclude that angiography is inadequate in and of itself to evaluate the functional significance of collateral vessels, and that "several physiologic variables" are most likely responsible for myocardial status in any given clinical situation. That so many adequately collateralized areas showed no evidence of subsequent improvement in myocardial perfusion also provided evidence that collaterals may often be of little or no significance. However, it is possible that such collaterals appeared too late after infarction to significantly improve overall perfusion. Since Kolibash's study, newer techniques have been used effectively to investigate the issues he raised and to characterize both the mechanism of the transformation of the native collaterals and assess their impact on myocardial perfusion and function—among them percutaneous transluminal coronary angioplasty (PTCA), ergovine-provocative spasm tests, and myocardial perfusion studies. Using PTCA, Rentrop demonstrated that collateral vessel filling jumps dramatically during coronary occlusion by balloon inflation—within ninety seconds of total occlusion. Filling improved in 15 of 16 patients; neither chest pain nor pre-inflation angina correlated with the extent of collateral filling, and coronary spasm did not occur.
=== Basic tools === The chemoproteomic toolkit is anchored by liquid chromatography-tandem mass spectrometry (LC-MS/MS or LC-MS) based quantitative proteomics, which allows for the near complete identification and relative quantification of complex proteomes in biological samples. In addition to proteomic analysis, the detection of post-translational modifications, like phosphorylation, glycosylation, acetylation, and recently ubiquitination, which give insight into the functional state of a cell, is also possible. The vast majority of proteomic studies are analyzed using high-resolution orbitrap mass spectrometers and samples are processed using a generalizable workflow. A standard procedure begins with sample lysis, in which proteins are extracted into a denaturing buffer containing salts, an agent that reduces disulfide bonds, such as dithiothreitol, and an alkylating agent that caps thiol groups, such as iodoacetamide. Denatured proteins are proteolysed, often with trypsin, and then separated from other mixture components prior to analysis via LC-MS/MS. For more accurate quantification, different samples can be reacted with isobaric tandem mass tags (TMTs), a form of chemical barcode that allows for sample multiplexing, and then pooled.
Sources: en.wikipedia.org
=== Controversies === In 2018 UA received funding from the Pioneer Fund, a non-profit institute which promotes scientific racism and eugenics. The funds were applied for by Aurelio Jose Figueredo, who directs the graduate program on human behavior and evolutionary psychology. Funds from the grant were used by Figueredo to attend the 2016 London Conference on Intelligence, where presentations on eugenics are given. Figueredo has also reviewed papers for Mankind Quarterly, a journal which has advocated for racial hierarchy. Figueredo has disavowed eugenics and racial inferiority.
== History == The therapeutic efficacy of subcutaneous pegcetacoplan in treating paroxysmal nocturnal hemoglobinuria has been established through several clinical trials. Initial phase I and II trials, such as PADDOCK, PALOMINO, and PHAROAH, evaluated pegcetacoplan in participants with paroxysmal nocturnal hemoglobinuria who had not received a complement inhibitor or had previously received eculizumab. These trials demonstrated that 1–2 years of pegcetacoplan treatment effectively controlled hemolysis and improved quality of life in participants with paroxysmal nocturnal hemoglobinuria. Building upon these findings, the efficacy of pegcetacoplan was further assessed in phase III trials. The PRINCE trial, a 26-week study, focused on complement inhibitor-naïve participants with paroxysmal nocturnal hemoglobinuria, while the PEGASUS trial, a 48-week multinational study, included complement inhibitor-treated participants with paroxysmal nocturnal hemoglobinuria. In these trials, subcutaneous pegcetacoplan was administered at a dosage of 1080 mg twice weekly, delivered as a 20-mL subcutaneous infusion. Participants had the option to self-administer the medication or have it administered by qualified research personnel.
A number of Neanderthal fossils had been discovered before their antiquity was fully understood. The first Neanderthal remains—Engis 2 (a skull)—were discovered in 1829 by Dutch/Belgian prehistorian Philippe-Charles Schmerling in the Grottes d'Engis, Belgium. He concluded that these "poorly developed" human remains must have been buried at the same time and by the same causes as the co-existing remains of extinct animal species. In 1848, Gibraltar 1 from Forbes' Quarry was presented to the Gibraltar Scientific Society by their Secretary Lieutenant Edmund Henry Réné Flint, but was thought to be a modern human skull. In 1856, local schoolteacher Johann Carl Fuhlrott recognised bones from Kleine Feldhofer Grotte in Neander Valley—Neanderthal 1—as distinct from modern humans, and gave them to German anthropologist Hermann Schaaffhausen to study in 1857. It comprised the cranium, thigh bones, right arm, left humerus and ulna, left ilium (hip bone), part of the right shoulder blade, and pieces of the ribs.
The ginkgo leaf is the symbol of the Urasenke school of Japanese tea ceremony. The tree is the official tree of the Japanese capital of Tokyo, and the symbol of Tokyo is a ginkgo leaf. Since 1948, the badge of Tokyo University has been two ginkgo leaves (designed by Shoichi Hoshino), which became the university logo in 2004 with a redesign. The logo of Osaka University has been a simplified ginkgo leaf since 1991 when designer Ikko Tanaka created it for the university's sixtieth anniversary. In professional sumo, wrestlers ranked in the two highest divisions (jūryō and makuuchi) wear an elaborate topknot called ōichōmage (大銀杏髷; lit. 'ginkgo-leaf topknot') because it resembles the leaf of the ginkgo tree. Ginkgo is an official tree of Seoul since 1971, designated by the Seoul Metropolitan Government.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.